Cargando…
Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience
The significance of EGFR targeted therapy in the lung adenocarcinoma is paramount. Several controlled clinical trials have reported considerable survival of EGFR mutation positive patients on receiving the EGFR tyrosine kinase inhibitor (TKI). However, the real-world evidence of benefits of EGFR TKI...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682910/ https://www.ncbi.nlm.nih.gov/pubmed/38033811 http://dx.doi.org/10.1016/j.jtocrr.2023.100566 |
_version_ | 1785151079966572544 |
---|---|
author | Chougule, Anuradha Chandrani, Pratik Noronha, Vanita Pange, Priyanka Kale, Shrutikaa Nikam, Ankita Nambiar, Kavya Marchande, Dipika Durve, Arpana Gupta, Vinod Jagtap, Vinita Tiwrekar, Priyanka Menon, Nandini Joshi, Amit Kaushal, Rajeev Pai, Trupti Patil, Vijay Maruti Dutt, Amit Banavali, Shripad Dinanath Prabhash, Kumar |
author_facet | Chougule, Anuradha Chandrani, Pratik Noronha, Vanita Pange, Priyanka Kale, Shrutikaa Nikam, Ankita Nambiar, Kavya Marchande, Dipika Durve, Arpana Gupta, Vinod Jagtap, Vinita Tiwrekar, Priyanka Menon, Nandini Joshi, Amit Kaushal, Rajeev Pai, Trupti Patil, Vijay Maruti Dutt, Amit Banavali, Shripad Dinanath Prabhash, Kumar |
author_sort | Chougule, Anuradha |
collection | PubMed |
description | The significance of EGFR targeted therapy in the lung adenocarcinoma is paramount. Several controlled clinical trials have reported considerable survival of EGFR mutation positive patients on receiving the EGFR tyrosine kinase inhibitor (TKI). However, the real-world evidence of benefits of EGFR TKI would be further useful to understand how the designated therapeutic regimen benefits the patients. In this study, we report a decade long real-world evidence of EGFR molecular testing in lung cancer at Tata Memorial Hospital (Mumbai, India). Laboratory and hospital records containing basic demographic details, clinical characteristics, treatment regimen, survival outcome were collected retrospectively. Statistical association and survival analysis were performed using the R programming. The cohort includes 9,053 lung cancer patients tested for EGFR mutations during 2011 to 2019. Baseline T790M and compound mutations were the only mutations observed co-occurring while all other EGFR mutations were mutually exclusive. Furthermore, the baseline T790M were also observed to be associated with TTF1 positivity, smoking and local metastasis. Overall survival of the patients harboring co-occurring compound mutations was significantly lesser than the other EGFR positive patients. Overall, our study suggests that EGFR TKI may provide real-world benefit to the lung cancer patients harboring mutually exclusive EGFR mutations. On the other hand, further systematic study is essential to develop better therapeutic regimen for co-occurring baseline EGFR T790M and other compound mutations. |
format | Online Article Text |
id | pubmed-10682910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106829102023-11-30 Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience Chougule, Anuradha Chandrani, Pratik Noronha, Vanita Pange, Priyanka Kale, Shrutikaa Nikam, Ankita Nambiar, Kavya Marchande, Dipika Durve, Arpana Gupta, Vinod Jagtap, Vinita Tiwrekar, Priyanka Menon, Nandini Joshi, Amit Kaushal, Rajeev Pai, Trupti Patil, Vijay Maruti Dutt, Amit Banavali, Shripad Dinanath Prabhash, Kumar JTO Clin Res Rep Brief Report The significance of EGFR targeted therapy in the lung adenocarcinoma is paramount. Several controlled clinical trials have reported considerable survival of EGFR mutation positive patients on receiving the EGFR tyrosine kinase inhibitor (TKI). However, the real-world evidence of benefits of EGFR TKI would be further useful to understand how the designated therapeutic regimen benefits the patients. In this study, we report a decade long real-world evidence of EGFR molecular testing in lung cancer at Tata Memorial Hospital (Mumbai, India). Laboratory and hospital records containing basic demographic details, clinical characteristics, treatment regimen, survival outcome were collected retrospectively. Statistical association and survival analysis were performed using the R programming. The cohort includes 9,053 lung cancer patients tested for EGFR mutations during 2011 to 2019. Baseline T790M and compound mutations were the only mutations observed co-occurring while all other EGFR mutations were mutually exclusive. Furthermore, the baseline T790M were also observed to be associated with TTF1 positivity, smoking and local metastasis. Overall survival of the patients harboring co-occurring compound mutations was significantly lesser than the other EGFR positive patients. Overall, our study suggests that EGFR TKI may provide real-world benefit to the lung cancer patients harboring mutually exclusive EGFR mutations. On the other hand, further systematic study is essential to develop better therapeutic regimen for co-occurring baseline EGFR T790M and other compound mutations. Elsevier 2023-08-23 /pmc/articles/PMC10682910/ /pubmed/38033811 http://dx.doi.org/10.1016/j.jtocrr.2023.100566 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Brief Report Chougule, Anuradha Chandrani, Pratik Noronha, Vanita Pange, Priyanka Kale, Shrutikaa Nikam, Ankita Nambiar, Kavya Marchande, Dipika Durve, Arpana Gupta, Vinod Jagtap, Vinita Tiwrekar, Priyanka Menon, Nandini Joshi, Amit Kaushal, Rajeev Pai, Trupti Patil, Vijay Maruti Dutt, Amit Banavali, Shripad Dinanath Prabhash, Kumar Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience |
title | Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience |
title_full | Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience |
title_fullStr | Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience |
title_full_unstemmed | Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience |
title_short | Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience |
title_sort | real-world evidence of egfr targeted therapy in nsclc– a brief report of decade long single center experience |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682910/ https://www.ncbi.nlm.nih.gov/pubmed/38033811 http://dx.doi.org/10.1016/j.jtocrr.2023.100566 |
work_keys_str_mv | AT chouguleanuradha realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT chandranipratik realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT noronhavanita realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT pangepriyanka realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT kaleshrutikaa realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT nikamankita realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT nambiarkavya realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT marchandedipika realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT durvearpana realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT guptavinod realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT jagtapvinita realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT tiwrekarpriyanka realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT menonnandini realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT joshiamit realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT kaushalrajeev realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT paitrupti realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT patilvijaymaruti realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT duttamit realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT banavalishripaddinanath realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience AT prabhashkumar realworldevidenceofegfrtargetedtherapyinnsclcabriefreportofdecadelongsinglecenterexperience |